Hyperbranched Polyamidoamine–RGD Peptide/si-circICA1 in the Treatment of Invasive Thyroid Cancer through Targeting of the miR-486-3p/SERPINA1 Axis

Abstract

Aim: This study aimed to identify molecular markers associated with papillary thyroid cancer (PTC) and investigate the therapeutic potential of targeted nanoscale drugs. Materials & methods: We analyzed the effects of circICA1 and miR-486-3p on B-CPAP cells’ proliferation, apoptosis, migration and invasion. The regulation of the miR-486-3p/SERPINA1 axis was explored using quantitative real-time reverse transcription PCR and western blot analyses for metastasis. In vivo, we evaluated the effects of hyperbranched polyamidoamine–RGD peptide/si-circICA1 on PTC growth and metastasis. Results: Enhanced miR-486-3p expression inhibits B-CPAP cells’ proliferation and invasion. si-circICA1 delivered via hyperbranched polyamidoamine–RGD peptide nanoparticles shows potential for treating metastasis in PTC. Conclusion: This study identifies key molecular mechanisms underlying PTC invasiveness and suggests a promising therapeutic strategy for PTC using targeted nanoscale drugs.

Graphical abstract

Keywords::

• circICA1
• HPAA-RGD
• miR-486-3p
• papillary thyroid cancer
• SERPINA1

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/nnm-2023-0211

Author contributions

Conceptualization: S Dong and X Xie. Methodology: S Dong, Q Xia, J Pan, X Du and Y Wu. Software: S Dong and Q Xia. Data curation: X Xie. Writing – original draft preparation: X Xie. Writing – review and editing: X Xie. Supervision: X Xie. Project administration: X Xie. Funding acquisition: S Dong.

Financial disclosure

This study was supported by the Foundation of the Natural Science Foundation of Zhejiang Province (no. LY21H160020). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The study procedure was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (no. 2019.793). Informed consent for collecting medical information was obtained from all patients at their visit.

Additional information

Funding

This study was supported by the Foundation of the Natural Science Foundation of Zhejiang Province (no. LY21H160020). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.